FindTrial
Sign In

Comparison of two nebulised medication combination in treating acute wheezing in children aged 1 to 5 years A Randomized controlled trial

Effect of nebulised budesonide and salbutamol versus ipratropium bromide and salbutamol in the management of acute exacerbation of wheeze moderate to severe in children aged 1 to 5 years A Randomized controlled trial - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/04/085680
Enrollment
84
Registered
2025-04-25
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J22- Unspecified acute lower respiratory infection

Interventions

Intervention1: Nebulised salbutamol and budesonide: Effect of nebulised budesonide and salbutamol versus ipratroipum bromide and salbutamol in the management of acute exacerbation of wheeze aged 1 to

Sponsors

RISHIKA A
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Children aged 1 to 5 years presenting with acute exacerbation of wheeze.

Exclusion criteria

Exclusion criteria: Life threatening exacerbations of wheeze. Patients who had received any corticosteroid therapy in the last 24 hours. Cardiovascular disorders Primary and secondary immunodeficiency Chronic illness Children presenting with mild exacerbation of wheeze (PRAM score 0 - 4 )

Design outcomes

Primary

MeasureTime frame
Improvement in wheeze severity score The primary outcome measure could assess the change in wheeze severity scores from baseline to a specified time point after treatment initiation. Timepoint: 60 minutes—

Secondary

MeasureTime frame
nilTimepoint: nil—

Countries

India

Contacts

Public ContactSUBASH S

SRM MEDICAL COLLEGE HOSPITAL AND RESEARCH CENTRE

drsubashss@yahoo.com9500675124

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026